Literature DB >> 24515630

Neuropsychological rehabilitation for multiple sclerosis.

Eija M Rosti-Otajärvi1, Päivi I Hämäläinen.   

Abstract

BACKGROUND: This is an update of the Cochrane review 'Neuropsychological rehabilitation for multiple sclerosis' (first published in The Cochrane Library 2011, Issue 11).Cognitive deficits are a common manifestation of multiple sclerosis (MS) and have a significant effect on the patient's quality of life. Alleviation of the harmful effects caused by these deficits should be a major goal of MS research and practice.
OBJECTIVES: To assess the effects of neuropsychological/cognitive rehabilitation on health-related factors, such as cognitive performance and emotional well-being in patients with MS. SEARCH
METHODS: The Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Trials Search Co-ordinator searched their Specialised Register which, among other sources, contains trials from CENTRAL (The Cochrane Library 2013, Issue 2), MEDLINE, EMBASE, CINAHL, LILACS, PEDro and clinical trials registries (28 May 2013). We contacted authors of the studies for additional information. SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-randomised trials evaluating the effects of neuropsychological rehabilitation in MS compared to other interventions or no intervention. DATA COLLECTION AND ANALYSIS: Two review authors individually judged the eligibility of the included studies, assessed risk of bias and extracted data. We combined results quantitatively in meta-analyses according to the intervention type: 1) cognitive training and 2) cognitive training combined with other neuropsychological rehabilitation methods. MAIN
RESULTS: Twenty studies (986 participants; 966 MS participants and 20 healthy controls) fulfilled the inclusion criteria. The mean age of the participants was 44.6 years, mean length of education was 12.3 years and 70% of the participants were women. Most of the participants had a relapsing-remitting course of disease. The mean Expanded Disability Status Scale score was 3.2 and the mean duration of disease was 14.0 years.On the basis of these studies, we found low-level evidence that neuropsychological rehabilitation reduces cognitive symptoms in MS. Cognitive training was found to improve memory span (standardised mean difference (SMD) 0.54, 95% confidence interval (CI) 0.20 to 0.88, P = 0.002) and working memory (SMD 0.33, 95% CI 0.09 to 0.57, P = 0.006). Cognitive training combined with other neuropsychological rehabilitation methods was found to improve attention (SMD 0.15, 95% CI 0.01 to 0.28, P = 0.03), immediate verbal memory (SMD 0.31, 95% CI 0.08 to 0.54, P = 0.008) and delayed memory (SMD 0.22, 95% CI 0.02 to 0.42, P = 0.03). There was no evidence of an effect of neuropsychological rehabilitation on emotional functions.The overall quality, as well as the comparability of the included studies, was relatively low due to methodological limitations and heterogeneity of interventions and outcome measures. Although most of the pooled results in the meta-analyses yielded no significant findings, 18 of the 20 studies showed some evidence of positive effects when the studies were individually analysed. AUTHORS'
CONCLUSIONS: This review found low-level evidence for positive effects of neuropsychological rehabilitation in MS. The interventions and outcome measures included in the review were heterogeneous, which limited the comparability of the studies. New trials may therefore change the strength and direction of the evidence.

Entities:  

Mesh:

Year:  2014        PMID: 24515630     DOI: 10.1002/14651858.CD009131.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  37 in total

1.  Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.

Authors:  Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

2.  Update on Recent Developments in Communication and Swallowing in Multiple Sclerosis.

Authors:  Francesca De Biagi; Leena Maria Heikkola; Sara Nordio; Leonie Ruhaak
Journal:  Int J MS Care       Date:  2020-12-28

3.  A pilot study of changes in functional brain activity during a working memory task after mSMT treatment: The MEMREHAB trial.

Authors:  M Huiskamp; E Dobryakova; G D Wylie; J DeLuca; N D Chiaravalloti
Journal:  Mult Scler Relat Disord       Date:  2016-03-24       Impact factor: 4.339

Review 4.  Neurorehabilitation: applied neuroplasticity.

Authors:  Fary Khan; Bhasker Amatya; Mary P Galea; Roman Gonzenbach; Jürg Kesselring
Journal:  J Neurol       Date:  2016-10-24       Impact factor: 4.849

Review 5.  Memory rehabilitation for people with multiple sclerosis.

Authors:  Lauren A Taylor; Jacqueline R Mhizha-Murira; Laura Smith; Kristy-Jane Potter; Dana Wong; Nikos Evangelou; Nadina B Lincoln; Roshan das Nair
Journal:  Cochrane Database Syst Rev       Date:  2021-10-18

Review 6.  Systematic, Evidence-Based Review of Exercise, Physical Activity, and Physical Fitness Effects on Cognition in Persons with Multiple Sclerosis.

Authors:  Brian M Sandroff; Robert W Motl; Mark R Scudder; John DeLuca
Journal:  Neuropsychol Rev       Date:  2016-07-22       Impact factor: 7.444

Review 7.  [New aspects of symptomatic MS treatment: Part 6 - cognitive dysfunction and rehabilitation].

Authors:  T Henze; W Feneberg; P Flachenecker; D Seidel; H Albrecht; M Starck; S G Meuth
Journal:  Nervenarzt       Date:  2018-04       Impact factor: 1.214

Review 8.  Fatigue as a symptom or comorbidity of neurological diseases.

Authors:  Iris-Katharina Penner; Friedemann Paul
Journal:  Nat Rev Neurol       Date:  2017-10-13       Impact factor: 42.937

9.  Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews.

Authors:  Bhasker Amatya; Fary Khan; Mary Galea
Journal:  Cochrane Database Syst Rev       Date:  2019-01-14

Review 10.  Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment.

Authors:  Charlene J Treanor; Una C McMenamin; Roisin F O'Neill; Chris R Cardwell; Mike J Clarke; Marie Cantwell; Michael Donnelly
Journal:  Cochrane Database Syst Rev       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.